Relapsed Acute Myeloid Leukemia Drug Industry Research Report 2025
Description
Summary
According to APO Research, the global Relapsed Acute Myeloid Leukemia Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Relapsed Acute Myeloid Leukemia Drug include 4SC AG, Amgen Inc., AbbVie Inc., AstraZeneca Plc, CTI BioPharma Corp., Cornerstone Pharmaceuticals, Inc., Celgene Corporation, Calithera Biosciences, Inc. and Bristol-Myers Squibb Company, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Relapsed Acute Myeloid Leukemia Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Relapsed Acute Myeloid Leukemia Drug.
The report will help the Relapsed Acute Myeloid Leukemia Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Relapsed Acute Myeloid Leukemia Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Relapsed Acute Myeloid Leukemia Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Relapsed Acute Myeloid Leukemia Drug Segment by Company
4SC AG
Amgen Inc.
AbbVie Inc.
AstraZeneca Plc
CTI BioPharma Corp.
Cornerstone Pharmaceuticals, Inc.
Celgene Corporation
Calithera Biosciences, Inc.
Bristol-Myers Squibb Company
Boston Biomedical, Inc.
Boehringer Ingelheim GmbH
BioLineRx, Ltd.
AVEO Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Astellas Pharma Inc.
Array BioPharma Inc.
Arog Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Relapsed Acute Myeloid Leukemia Drug Segment by Type
aNK Program
AT-9283
BI-836858
BL-8040
Binimetinib
Others
Relapsed Acute Myeloid Leukemia Drug Segment by Application
Clinic
Hospital
Others
Relapsed Acute Myeloid Leukemia Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Relapsed Acute Myeloid Leukemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Relapsed Acute Myeloid Leukemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Relapsed Acute Myeloid Leukemia Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Relapsed Acute Myeloid Leukemia Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Relapsed Acute Myeloid Leukemia Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Relapsed Acute Myeloid Leukemia Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Relapsed Acute Myeloid Leukemia Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Relapsed Acute Myeloid Leukemia Drug include 4SC AG, Amgen Inc., AbbVie Inc., AstraZeneca Plc, CTI BioPharma Corp., Cornerstone Pharmaceuticals, Inc., Celgene Corporation, Calithera Biosciences, Inc. and Bristol-Myers Squibb Company, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Relapsed Acute Myeloid Leukemia Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Relapsed Acute Myeloid Leukemia Drug.
The report will help the Relapsed Acute Myeloid Leukemia Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Relapsed Acute Myeloid Leukemia Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Relapsed Acute Myeloid Leukemia Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Relapsed Acute Myeloid Leukemia Drug Segment by Company
4SC AG
Amgen Inc.
AbbVie Inc.
AstraZeneca Plc
CTI BioPharma Corp.
Cornerstone Pharmaceuticals, Inc.
Celgene Corporation
Calithera Biosciences, Inc.
Bristol-Myers Squibb Company
Boston Biomedical, Inc.
Boehringer Ingelheim GmbH
BioLineRx, Ltd.
AVEO Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Astellas Pharma Inc.
Array BioPharma Inc.
Arog Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Relapsed Acute Myeloid Leukemia Drug Segment by Type
aNK Program
AT-9283
BI-836858
BL-8040
Binimetinib
Others
Relapsed Acute Myeloid Leukemia Drug Segment by Application
Clinic
Hospital
Others
Relapsed Acute Myeloid Leukemia Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Relapsed Acute Myeloid Leukemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Relapsed Acute Myeloid Leukemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Relapsed Acute Myeloid Leukemia Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Relapsed Acute Myeloid Leukemia Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Relapsed Acute Myeloid Leukemia Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Relapsed Acute Myeloid Leukemia Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
133 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size (2020-2031)
- 2.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales (2020-2031)
- 2.2.3 Global Relapsed Acute Myeloid Leukemia Drug Market Average Price (2020-2031)
- 2.3 Relapsed Acute Myeloid Leukemia Drug by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 aNK Program
- 2.3.3 AT-9283
- 2.3.4 BI-836858
- 2.3.5 BL-8040
- 2.3.6 Binimetinib
- 2.3.7 Others
- 2.4 Relapsed Acute Myeloid Leukemia Drug by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Relapsed Acute Myeloid Leukemia Drug Sales (K Units) of Manufacturers (2020-2025)
- 3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue of Manufacturers (2020-2025)
- 3.4 Global Relapsed Acute Myeloid Leukemia Drug Average Price by Manufacturers (2020-2025)
- 3.5 Global Relapsed Acute Myeloid Leukemia Drug Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Product Type & Application
- 3.8 Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Established Date
- 3.9 Global Relapsed Acute Myeloid Leukemia Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 4SC AG
- 4.1.1 4SC AG Company Information
- 4.1.2 4SC AG Business Overview
- 4.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.1.5 4SC AG Recent Developments
- 4.2 Amgen Inc.
- 4.2.1 Amgen Inc. Company Information
- 4.2.2 Amgen Inc. Business Overview
- 4.2.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.2.5 Amgen Inc. Recent Developments
- 4.3 AbbVie Inc.
- 4.3.1 AbbVie Inc. Company Information
- 4.3.2 AbbVie Inc. Business Overview
- 4.3.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.3.5 AbbVie Inc. Recent Developments
- 4.4 AstraZeneca Plc
- 4.4.1 AstraZeneca Plc Company Information
- 4.4.2 AstraZeneca Plc Business Overview
- 4.4.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.4.5 AstraZeneca Plc Recent Developments
- 4.5 CTI BioPharma Corp.
- 4.5.1 CTI BioPharma Corp. Company Information
- 4.5.2 CTI BioPharma Corp. Business Overview
- 4.5.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.5.5 CTI BioPharma Corp. Recent Developments
- 4.6 Cornerstone Pharmaceuticals, Inc.
- 4.6.1 Cornerstone Pharmaceuticals, Inc. Company Information
- 4.6.2 Cornerstone Pharmaceuticals, Inc. Business Overview
- 4.6.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.6.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
- 4.7 Celgene Corporation
- 4.7.1 Celgene Corporation Company Information
- 4.7.2 Celgene Corporation Business Overview
- 4.7.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.7.5 Celgene Corporation Recent Developments
- 4.8 Calithera Biosciences, Inc.
- 4.8.1 Calithera Biosciences, Inc. Company Information
- 4.8.2 Calithera Biosciences, Inc. Business Overview
- 4.8.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.8.5 Calithera Biosciences, Inc. Recent Developments
- 4.9 Bristol-Myers Squibb Company
- 4.9.1 Bristol-Myers Squibb Company Company Information
- 4.9.2 Bristol-Myers Squibb Company Business Overview
- 4.9.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.9.5 Bristol-Myers Squibb Company Recent Developments
- 4.10 Boston Biomedical, Inc.
- 4.10.1 Boston Biomedical, Inc. Company Information
- 4.10.2 Boston Biomedical, Inc. Business Overview
- 4.10.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.10.5 Boston Biomedical, Inc. Recent Developments
- 4.11 Boehringer Ingelheim GmbH
- 4.11.1 Boehringer Ingelheim GmbH Company Information
- 4.11.2 Boehringer Ingelheim GmbH Business Overview
- 4.11.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.11.5 Boehringer Ingelheim GmbH Recent Developments
- 4.12 BioLineRx, Ltd.
- 4.12.1 BioLineRx, Ltd. Company Information
- 4.12.2 BioLineRx, Ltd. Business Overview
- 4.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.12.5 BioLineRx, Ltd. Recent Developments
- 4.13 AVEO Pharmaceuticals, Inc.
- 4.13.1 AVEO Pharmaceuticals, Inc. Company Information
- 4.13.2 AVEO Pharmaceuticals, Inc. Business Overview
- 4.13.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.13.5 AVEO Pharmaceuticals, Inc. Recent Developments
- 4.14 Astex Pharmaceuticals, Inc.
- 4.14.1 Astex Pharmaceuticals, Inc. Company Information
- 4.14.2 Astex Pharmaceuticals, Inc. Business Overview
- 4.14.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.14.5 Astex Pharmaceuticals, Inc. Recent Developments
- 4.15 Astellas Pharma Inc.
- 4.15.1 Astellas Pharma Inc. Company Information
- 4.15.2 Astellas Pharma Inc. Business Overview
- 4.15.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.15.5 Astellas Pharma Inc. Recent Developments
- 4.16 Array BioPharma Inc.
- 4.16.1 Array BioPharma Inc. Company Information
- 4.16.2 Array BioPharma Inc. Business Overview
- 4.16.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.16.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.16.5 Array BioPharma Inc. Recent Developments
- 4.17 Arog Pharmaceuticals, Inc.
- 4.17.1 Arog Pharmaceuticals, Inc. Company Information
- 4.17.2 Arog Pharmaceuticals, Inc. Business Overview
- 4.17.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.17.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.17.5 Arog Pharmaceuticals, Inc. Recent Developments
- 4.18 Agios Pharmaceuticals, Inc.
- 4.18.1 Agios Pharmaceuticals, Inc. Company Information
- 4.18.2 Agios Pharmaceuticals, Inc. Business Overview
- 4.18.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.18.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.18.5 Agios Pharmaceuticals, Inc. Recent Developments
- 4.19 Actinium Pharmaceuticals, Inc.
- 4.19.1 Actinium Pharmaceuticals, Inc. Company Information
- 4.19.2 Actinium Pharmaceuticals, Inc. Business Overview
- 4.19.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.19.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- 4.19.5 Actinium Pharmaceuticals, Inc. Recent Developments
- 5 Global Relapsed Acute Myeloid Leukemia Drug Market Scenario by Region
- 5.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2020-2031
- 5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2020-2025
- 5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2026-2031
- 5.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2020-2031
- 5.3.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2020-2025
- 5.3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2026-2031
- 5.4 North America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
- 5.4.1 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2031)
- 5.4.3 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
- 5.5.1 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2031)
- 5.5.3 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
- 5.7.1 South America Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2031)
- 5.7.3 South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2020-2031)
- 6.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2020-2031) & (K Units)
- 6.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2020-2031)
- 6.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2020-2031)
- 6.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2020-2031)
- 6.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2020-2031)
- 7.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2020-2031) & (K Units)
- 7.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2020-2031)
- 7.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2020-2031)
- 7.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2020-2031)
- 7.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Relapsed Acute Myeloid Leukemia Drug Value Chain Analysis
- 8.1.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Relapsed Acute Myeloid Leukemia Drug Production Mode & Process
- 8.2 Relapsed Acute Myeloid Leukemia Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Relapsed Acute Myeloid Leukemia Drug Distributors
- 8.2.3 Relapsed Acute Myeloid Leukemia Drug Customers
- 9 Global Relapsed Acute Myeloid Leukemia Drug Analyzing Market Dynamics
- 9.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
- 9.2 Relapsed Acute Myeloid Leukemia Drug Industry Drivers
- 9.3 Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges
- 9.4 Relapsed Acute Myeloid Leukemia Drug Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Relapsed Acute Myeloid Leukemia Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Relapsed Acute Myeloid Leukemia Drug Sales (K Units) of Manufacturers (2020-2025)
- Table 7. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Relapsed Acute Myeloid Leukemia Drug Revenue of Manufacturers (2020-2025)
- Table 9. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Relapsed Acute Myeloid Leukemia Drug Average Price (US$/Unit) of Manufacturers (2020-2025)
- Table 11. Global Relapsed Acute Myeloid Leukemia Drug Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Product Type & Application
- Table 14. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Relapsed Acute Myeloid Leukemia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. 4SC AG Company Information
- Table 19. 4SC AG Business Overview
- Table 20. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 21. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 22. 4SC AG Recent Developments
- Table 23. Amgen Inc. Company Information
- Table 24. Amgen Inc. Business Overview
- Table 25. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 26. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 27. Amgen Inc. Recent Developments
- Table 28. AbbVie Inc. Company Information
- Table 29. AbbVie Inc. Business Overview
- Table 30. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 31. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 32. AbbVie Inc. Recent Developments
- Table 33. AstraZeneca Plc Company Information
- Table 34. AstraZeneca Plc Business Overview
- Table 35. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 36. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 37. AstraZeneca Plc Recent Developments
- Table 38. CTI BioPharma Corp. Company Information
- Table 39. CTI BioPharma Corp. Business Overview
- Table 40. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 41. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 42. CTI BioPharma Corp. Recent Developments
- Table 43. Cornerstone Pharmaceuticals, Inc. Company Information
- Table 44. Cornerstone Pharmaceuticals, Inc. Business Overview
- Table 45. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 46. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 47. Cornerstone Pharmaceuticals, Inc. Recent Developments
- Table 48. Celgene Corporation Company Information
- Table 49. Celgene Corporation Business Overview
- Table 50. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 51. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 52. Celgene Corporation Recent Developments
- Table 53. Calithera Biosciences, Inc. Company Information
- Table 54. Calithera Biosciences, Inc. Business Overview
- Table 55. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 56. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 57. Calithera Biosciences, Inc. Recent Developments
- Table 58. Bristol-Myers Squibb Company Company Information
- Table 59. Bristol-Myers Squibb Company Business Overview
- Table 60. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 61. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 62. Bristol-Myers Squibb Company Recent Developments
- Table 63. Boston Biomedical, Inc. Company Information
- Table 64. Boston Biomedical, Inc. Business Overview
- Table 65. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 66. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 67. Boston Biomedical, Inc. Recent Developments
- Table 68. Boehringer Ingelheim GmbH Company Information
- Table 69. Boehringer Ingelheim GmbH Business Overview
- Table 70. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 71. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 72. Boehringer Ingelheim GmbH Recent Developments
- Table 73. BioLineRx, Ltd. Company Information
- Table 74. BioLineRx, Ltd. Business Overview
- Table 75. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 76. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 77. BioLineRx, Ltd. Recent Developments
- Table 78. AVEO Pharmaceuticals, Inc. Company Information
- Table 79. AVEO Pharmaceuticals, Inc. Business Overview
- Table 80. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 81. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 82. AVEO Pharmaceuticals, Inc. Recent Developments
- Table 83. Astex Pharmaceuticals, Inc. Company Information
- Table 84. Astex Pharmaceuticals, Inc. Business Overview
- Table 85. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 86. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 87. Astex Pharmaceuticals, Inc. Recent Developments
- Table 88. Astellas Pharma Inc. Company Information
- Table 89. Astellas Pharma Inc. Business Overview
- Table 90. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 91. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 92. Astellas Pharma Inc. Recent Developments
- Table 93. Array BioPharma Inc. Company Information
- Table 94. Array BioPharma Inc. Business Overview
- Table 95. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 96. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 97. Array BioPharma Inc. Recent Developments
- Table 98. Arog Pharmaceuticals, Inc. Company Information
- Table 99. Arog Pharmaceuticals, Inc. Business Overview
- Table 100. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 101. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 102. Arog Pharmaceuticals, Inc. Recent Developments
- Table 103. Agios Pharmaceuticals, Inc. Company Information
- Table 104. Agios Pharmaceuticals, Inc. Business Overview
- Table 105. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 106. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 107. Agios Pharmaceuticals, Inc. Recent Developments
- Table 108. Actinium Pharmaceuticals, Inc. Company Information
- Table 109. Actinium Pharmaceuticals, Inc. Business Overview
- Table 110. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 111. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
- Table 112. Actinium Pharmaceuticals, Inc. Recent Developments
- Table 113. Global Relapsed Acute Myeloid Leukemia Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 114. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2020-2025) & (K Units)
- Table 115. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2020-2025)
- Table 116. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2026-2031) & (K Units)
- Table 117. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2026-2031)
- Table 118. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2020-2025) & (US$ Million)
- Table 119. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2020-2025)
- Table 120. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2026-2031) & (US$ Million)
- Table 121. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2026-2031)
- Table 122. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 123. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2025) & (K Units)
- Table 124. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2026-2031) & (K Units)
- Table 125. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 126. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 127. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 128. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2025) & (K Units)
- Table 129. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2026-2031) & (K Units)
- Table 130. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 131. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 132. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 133. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2025) & (K Units)
- Table 134. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2026-2031) & (K Units)
- Table 135. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 136. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 137. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 138. South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2025) & (K Units)
- Table 139. South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2026-2031) & (K Units)
- Table 140. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 141. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 142. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 143. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2020-2025) & (K Units)
- Table 144. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2026-2031) & (K Units)
- Table 145. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 146. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 147. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2020-2025) & (K Units)
- Table 148. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2026-2031) & (K Units)
- Table 149. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2020-2025)
- Table 150. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2026-2031)
- Table 151. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2020-2025) & (US$ Million)
- Table 152. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2026-2031) & (US$ Million)
- Table 153. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2020-2025)
- Table 154. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2026-2031)
- Table 155. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2020-2025) & (US$/Unit)
- Table 156. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2026-2031) & (US$/Unit)
- Table 157. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2020-2025) & (K Units)
- Table 158. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2026-2031) & (K Units)
- Table 159. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2020-2025)
- Table 160. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2026-2031)
- Table 161. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2020-2025) & (US$ Million)
- Table 162. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2026-2031) & (US$ Million)
- Table 163. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2020-2025)
- Table 164. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2026-2031)
- Table 165. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2020-2025) & (US$/Unit)
- Table 166. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2026-2031) & (US$/Unit)
- Table 167. Key Raw Materials
- Table 168. Raw Materials Key Suppliers
- Table 169. Relapsed Acute Myeloid Leukemia Drug Distributors List
- Table 170. Relapsed Acute Myeloid Leukemia Drug Customers List
- Table 171. Relapsed Acute Myeloid Leukemia Drug Industry Trends
- Table 172. Relapsed Acute Myeloid Leukemia Drug Industry Drivers
- Table 173. Relapsed Acute Myeloid Leukemia Drug Industry Restraints
- Table 174. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Relapsed Acute Myeloid Leukemia Drug Product Image
- Figure 5. Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Relapsed Acute Myeloid Leukemia Drug Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Relapsed Acute Myeloid Leukemia Drug Sales (2020-2031) & (K Units)
- Figure 8. Global Relapsed Acute Myeloid Leukemia Drug Average Price (US$/Unit) & (2020-2031)
- Figure 9. aNK Program Product Image
- Figure 10. AT
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
